Treatment of Concurrent Minimal Change Disease and Epstein Barr Virus–Driven Post-transplant Lymphoproliferative Disorder With Rituximab Following Hematopoietic Stem Cell Transplantation

Detalles Bibliográficos
Autores principales: Ainley, Louise, Law, Steven, Heptinstall, Lauren, Rodriguez-Justo, Manuel, Thomson, Kirsty, Pepper, Ruth J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Nephrology Rounds
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783564/
https://www.ncbi.nlm.nih.gov/pubmed/33426402
http://dx.doi.org/10.1016/j.ekir.2020.10.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783564/
https://www.ncbi.nlm.nih.gov/pubmed/33426402
http://dx.doi.org/10.1016/j.ekir.2020.10.012

Ejemplares similares